"Spiral Escalation–De-escalation" Therapy for End-stage Heart Failure Recognized as a Major Clinical Technology in Guangzhou

End-stage heart failure is often described as "the final battlefield of cardiovascular disease." Without effective intervention, the one-year survival rate remains below 50%. Traditional treatments struggle to bridge acute rescue and long-term recovery, leaving patients with limited therapeutic options.

• The "Spiral Escalation–De-escalation" therapy introduces a comprehensive, full-cycle treatment model that dynamically adapts to the patient's condition—from life-saving support to rehabilitation and quality recovery.

• The project, "Standardized Construction and Clinical Pathway Optimization of Spiral Mechanical Support for End-stage Heart Failure," has been included in the 2026–2028 Major Clinical Technology List released by the Guangzhou Health Commission.

• This recognition reflects continued progress in advancing China's independent and clinically proven approaches to advanced heart failure treatment.

A Full-cycle Treatment Framework

The "Spiral Escalation–De-escalation" approach provides a continuous pathway that integrates acute support, transition care, and rehabilitation into one cohesive system.

• Enables flexible adjustment of treatment intensity according to disease progression.

• Addresses the long-standing "treatment gap" between emergency support and long-term management.

• Creates a dynamic protection mechanism that transforms care from life-saving to quality-enhancing.

Three Core Technical Innovations

The therapy's effectiveness is driven by several major technical advancements:

• Integrated ECMO + Extra VAD support for efficient ventricular unloading and shorter ECMO duration.

• Minimally invasive bridge technique allowing seamless switch to durable LVAD therapy without repeat surgery.

• Stepwise LVAD downregulation and intelligent anticoagulation management for safer device weaning and reduced complication risks.

These innovations have been clinically validated in multiple centers, improving patient survival, reducing ICU stays, and enhancing recovery outcomes.

Enabling Technology: magAssist MoyoAssist® Extra VAD

As the key enabling technology within this therapeutic system, the MoyoAssist® Extra VAD developed by magAssist provides essential mechanical circulatory support.

• Designed for seamless integration with other extracorporeal systems to support personalized treatment strategies.

• magAssist continues to advance R&D and clinical collaboration, expanding the reach of the "China Heart Solution" in the global cardiovascular field.